422 related articles for article (PubMed ID: 19410619)
1. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U
Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619
[TBL] [Abstract][Full Text] [Related]
2. N-glycan analysis by CGE-LIF: profiling influenza A virus hemagglutinin N-glycosylation during vaccine production.
Schwarzer J; Rapp E; Reichl U
Electrophoresis; 2008 Nov; 29(20):4203-14. PubMed ID: 18925582
[TBL] [Abstract][Full Text] [Related]
3. Impact of cultivation conditions on N-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture.
Rödig JV; Rapp E; Bohne J; Kampe M; Kaffka H; Bock A; Genzel Y; Reichl U
Biotechnol Bioeng; 2013 Jun; 110(6):1691-703. PubMed ID: 23297157
[TBL] [Abstract][Full Text] [Related]
4. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-Flow cytometry and mathematical modeling.
Schulze-Horsel J; Schulze M; Agalaridis G; Genzel Y; Reichl U
Vaccine; 2009 May; 27(20):2712-22. PubMed ID: 19428884
[TBL] [Abstract][Full Text] [Related]
5. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
Hütter J; Rödig JV; Höper D; Seeberger PH; Reichl U; Rapp E; Lepenies B
J Immunol; 2013 Jan; 190(1):220-30. PubMed ID: 23225881
[TBL] [Abstract][Full Text] [Related]
6. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
8. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells.
Zhirnov OP; Vorobjeva IV; Saphonova OA; Poyarkov SV; Ovcharenko AV; Anhlan D; Malyshev NA
J Clin Virol; 2009 Aug; 45(4):322-33. PubMed ID: 19546028
[TBL] [Abstract][Full Text] [Related]
9. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation.
Saito T; Nakaya Y; Suzuki T; Ito R; Saito T; Saito H; Takao S; Sahara K; Odagiri T; Murata T; Usui T; Suzuki Y; Tashiro M
J Med Virol; 2004 Oct; 74(2):336-43. PubMed ID: 15332284
[TBL] [Abstract][Full Text] [Related]
10. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
[TBL] [Abstract][Full Text] [Related]
11. Differential receptor binding affinities of influenza hemagglutinins on glycan arrays.
Liao HY; Hsu CH; Wang SC; Liang CH; Yen HY; Su CY; Chen CH; Jan JT; Ren CT; Chen CH; Cheng TJ; Wu CY; Wong CH
J Am Chem Soc; 2010 Oct; 132(42):14849-56. PubMed ID: 20882975
[TBL] [Abstract][Full Text] [Related]
12. Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype.
Mo C; Yamagata R; Pan A; Reddy J; Hazari N; Duke G
J Virol Methods; 2008 Jun; 150(1-2):63-9. PubMed ID: 18423899
[TBL] [Abstract][Full Text] [Related]
13. Developing cell culture-derived pandemic vaccines.
Barrett PN; Portsmouth D; Ehrlich HJ
Curr Opin Mol Ther; 2010 Feb; 12(1):21-30. PubMed ID: 20140813
[TBL] [Abstract][Full Text] [Related]
14. Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs.
Chen Z; Aspelund A; Jin H
Vaccine; 2008 Jan; 26(3):361-71. PubMed ID: 18079027
[TBL] [Abstract][Full Text] [Related]
15. Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D:
Parsons LM; An Y; Qi L; White MR; van der Woude R; Hartshorn KL; Taubenberger JK; de Vries RP; Cipollo JF
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826991
[TBL] [Abstract][Full Text] [Related]
16. [Type and subtype distribution of influenza virus and genetic evolution of hemagglutinin in Shanghai area in duration of 2004 - 2008].
Yang JX; Ju LW; Jiang LF; Shi Q; Jiang QW; Zhang YY; Zhou YB; Shen HG; Tan YY
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Apr; 43(4):305-8. PubMed ID: 19534952
[TBL] [Abstract][Full Text] [Related]
17.
An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
[TBL] [Abstract][Full Text] [Related]
18. Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.
Harvey R; Hamill M; Robertson JS; Minor PD; Vodeiko GM; Weir JP; Takahashi H; Harada Y; Itamura S; Bamford P; Dalla Pozza T; Engelhardt OG
Biologicals; 2012 Jan; 40(1):96-9. PubMed ID: 22244521
[TBL] [Abstract][Full Text] [Related]
19. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
[TBL] [Abstract][Full Text] [Related]
20. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent.
Opitz L; Zimmermann A; Lehmann S; Genzel Y; Lübben H; Reichl U; Wolff MW
J Virol Methods; 2008 Dec; 154(1-2):61-8. PubMed ID: 18840469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
